Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.
Badiou
Stéphanie
S
Department of Biochemistry, University Hospital, Montpellier 34295, France.
De Boever
Corinne Merle
CM
Dupuy
Anne-Marie
AM
Baillat
Vincent
V
Cristol
Jean-Paul
JP
Reynes
Jacques
J
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D001161:Arteriosclerosis / Q000139:chemically induced; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced*; D008055:Lipids / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood*; D061466:Lopinavir; D011744:Pyrimidinones / Q000009:adverse effects*; D019438:Ritonavir / Q000009:adverse effects*
D017320:HIV Protease Inhibitors; D008055:Lipids; D008077:Lipoproteins, LDL; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir